Search

Your search keyword '"Bria, Emilio"' showing total 407 results
Start Over Author "Bria, Emilio" Search Limiters Academic (Peer-Reviewed) Journals
407 results on '"Bria, Emilio"'

1. Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives

Author

Simbolo, Michele, Centonze, Giovanni, Gkountakos, Anastasios, Monti, Valentina, Maisonneuve, Patrick, Golovco, Stela, Sabella, Giovanna, Del Gobbo, Alessandro, Gobbo, Stefano, Ferrero, Stefano, Fabbri, Alessandra, Pardo, Carlotta, Garzone, Giovanna, Prinzi, Natalie, Pusceddu, Sara, Testi, Adele, Rolli, Luigi, Mangogna, Alessandro, Bercich, Luisa, Benvenuti, Mauro Roberto, Bria, Emilio, Pilotto, Sara, Berruti, Alfredo, Pastorino, Ugo, Capella, Carlo, Infante, Maurizio, Milella, Michele, Scarpa, Aldo, and Milione, Massimo

Published
2024
Full Text
View/download PDF

2. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

Author

Giordani, Elena, Allegretti, Matteo, Sinibaldi, Alberto, Michelotti, Francesco, Ferretti, Gianluigi, Ricciardi, Elena, Ziccheddu, Giovanna, Valenti, Fabio, Di Martino, Simona, Ercolani, Cristiana, Giannarelli, Diana, Arpino, Grazia, Gori, Stefania, Omarini, Claudia, Zambelli, Alberto, Bria, Emilio, Paris, Ida, Buglioni, Simonetta, Giacomini, Patrizio, and Fabi, Alessandra

Published
2024
Full Text
View/download PDF

3. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)

Author

Vita, Emanuele, Stefani, Alessio, Piro, Geny, Mastrantoni, Luca, Cintoni, Marco, Cicchetti, Giuseppe, Sparagna, Ileana, Monaca, Federico, Horn, Guido, Russo, Jacopo, Barone, Diletta, Di Salvatore, Mariantonietta, Trisolini, Rocco, Lococo, Filippo, Mazzarella, Ciro, Cancellieri, Alessandra, Carbone, Carmine, Larici, Anna Rita, Mele, Maria Cristina, Pilotto, Sara, Milella, Michele, Tortora, Giampaolo, and Bria, Emilio

Published
2023
Full Text
View/download PDF

5. Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Author

Miglietta, Federica, Pontolillo, Letizia, De Angelis, Carmine, Caputo, Roberta, Marino, Monica, Bria, Emilio, Di Rienzo, Rossana, Verrazzo, Annarita, Buonerba, Carlo, Tortora, Giampaolo, Di Lorenzo, Giuseppe, Del Mastro, Lucia, Giuliano, Mario, Montemurro, Filippo, Puglisi, Fabio, Guarneri, Valentina, De Laurentiis, Michelino, Scafuri, Luca, and Arpino, Grazia

Published
2024
Full Text
View/download PDF

6. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

7. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

Author

Agostini, Antonio, Guerriero, Ilaria, Piro, Geny, Quero, Giuseppe, Roberto, Luca, Esposito, Annachiara, Caggiano, Alessia, Priori, Lorenzo, Scaglione, Giulia, De Sanctis, Francesco, Sistigu, Antonella, Musella, Martina, Larghi, Alberto, Rizzatti, Gianenrico, Lucchetti, Donatella, Alfieri, Sergio, Sgambato, Alessandro, Bria, Emilio, Bizzozero, Laura, Arena, Sabrina, Ugel, Stefano, Corbo, Vincenzo, Tortora, Giampaolo, and Carbone, Carmine

Published
2023
Full Text
View/download PDF

8. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study

Author

Lococo, Filippo, Boldrini, Luca, Diepriye, Charles-Davies, Evangelista, Jessica, Nero, Camilla, Flamini, Sara, Minucci, Angelo, De Paolis, Elisa, Vita, Emanuele, Cesario, Alfredo, Annunziata, Salvatore, Calcagni, Maria Lucia, Chiappetta, Marco, Cancellieri, Alessandra, Larici, Anna Rita, Cicchetti, Giuseppe, Troost, Esther G.C., Ádány, Róza, Farré, Núria, Öztürk, Ece, Van Doorne, Dominique, Leoncini, Fausto, Urbani, Andrea, Trisolini, Rocco, Bria, Emilio, Giordano, Alessandro, Rindi, Guido, Sala, Evis, Tortora, Giampaolo, Valentini, Vincenzo, Boccia, Stefania, Margaritora, Stefano, and Scambia, Giovanni

Published
2023
Full Text
View/download PDF

9. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)

Author

Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, and Bria, Emilio

Published
2023
Full Text
View/download PDF

11. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

Author

Passiglia, Francesco, Lucia Reale, Maria, Lo Russo, Giuseppe, Pasello, Giulia, Minuti, Gabriele, Bulotta, Alessandra, Galetta, Domenico, Pelizzari, Giacomo, Sini, Claudio, Bria, Emilio, Roca, Elisa, Pilotto, Sara, Genova, Carlo, Metro, Giulio, Citarella, Fabrizio, Chiari, Rita, Cortinovis, Diego, Delmonte, Angelo, Russo, Alessandro, Tiseo, Marcello, Cerea, Giulio, Carta, Annamaria, Scotti, Vieri, Vavalà, Tiziana, Brambilla, Marta, Buffoni, Lucio, Buosi, Roberta, Catania, Chiara, Gori, Stefania, Grisanti, Salvatore, Agustoni, Francesco, Garbo, Edoardo, Malapelle, Umberto, and Novello, Silvia

Published
2024
Full Text
View/download PDF

12. Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation

Author

Dieci, Maria Vittoria, Carbognin, Luisa, Miglietta, Federica, Canino, Fabio, Giorgi, Carlo Alberto, Cumerlato, Enrico, Amato, Ottavia, Massa, Davide, Griguolo, Gaia, Genovesi, Elisa, Garufi, Giovanna, Giannarelli, Diana, Tornincasa, Antonio, Trudu, Lucia, Michieletto, Silvia, Saibene, Tania, Lo Mele, Marcello, Fassan, Matteo, Zarrilli, Giovanni, Piacentini, Federico, Bria, Emilio, and Guarneri, Valentina

Published
2023
Full Text
View/download PDF

13. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies

Author

Miglietta, Federica, Dieci, Maria Vittoria, Giarratano, Tommaso, Torri, Valter, Giuliano, Mario, Zustovich, Fable, Mion, Marta, Tondini, Carlo Alberto, De Rossi, Costanza, Bria, Emilio, Franchi, Michela, Merlini, Laura, Giannatiempo, Rosa, Russo, Daniela, Fotia, Vittoria, Poletti, Paola, Caremoli, Elena Rota, Arpino, Maria Grazia, De Salvo, Gian Luca, Zambelli, Alberto, and Guarneri, Valentina

Published
2023
Full Text
View/download PDF

15. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results

Author

Lococo, Filippo, Cancellieri, Alessandra, Chiappetta, Marco, Leonetti, Alessandro, Cardillo, Giuseppe, Zanelli, Francesca, Mangiameli, Giuseppe, Toschi, Luca, Guggino, Gianluca, Romano, Francesco Jacopo, Leuzzi, Giovanni, Proto, Claudia, Spaggiari, Lorenzo, De Marinis, Filippo, Vita, Emanuele, Ampollini, Luca, Margaritora, Stefano, Tiseo, Marcello, and Bria, Emilio

Published
2023
Full Text
View/download PDF

16. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Author

Aldea, Mihaela, Marinello, Arianna, Duruisseaux, Michael, Zrafi, Wael, Conci, Nicole, Massa, Giacomo, Metro, Giulio, Monnet, Isabelle, Gomez Iranzo, Patricia, Tabbo, Fabrizio, Bria, Emilio, Guisier, Florian, Vasseur, Damien, Lindsay, Colin R., Ponce-Aix, Santiago, Cousin, Sophie, Citarella, Fabrizio, Fallet, Vincent, Minatta, Jose Nicolas, Eisert, Anna, de Saint Basile, Hortense, Audigier-Valette, Clarisse, Mezquita, Laura, Calles, Antonio, Mountzios, Giannis, Tagliamento, Marco, Remon Masip, Jordi, Raimbourg, Judith, Terrisse, Safae, Russo, Alessandro, Cortinovis, Diego, Rochigneux, Philippe, Pinato, David James, Cortellini, Alessio, Leonce, Camille, Gazzah, Anas, Ghigna, Maria-Rosa, Ferrara, Roberto, Dall’Olio, Filippo Gustavo, Passiglia, Francesco, Ludovini, Vienna, Barlesi, Fabrice, Felip, Enriqueta, Planchard, David, and Besse, Benjamin

Published
2023
Full Text
View/download PDF

19. Predictive and prognostic effect of computed tomography–derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer

Author

Trestini, Ilaria, Caldart, Alberto, Cintoni, Marco, Sperduti, Isabella, Drudi, Alessandro, Aluffi, Gregorio, Fiorio, Elena, Parolin, Veronica, Zambonin, Valentina, Zanelli, Sara, Tregnago, Daniela, Avancini, Alice, Pilotto, Sara, Aprili, Irene, Zandonà, Emanuela, D'Onofrio, Mirko, Mele, Maria Cristina, Gasbarrini, Antonio, Scambia, Giovanni, Tortora, Giampaolo, Milella, Michele, Bria, Emilio, and Carbognin, Luisa

Published
2023
Full Text
View/download PDF

20. Loss of FGFR4 promotes the malignant phenotype of PDAC

Author

D’Agosto, Sabrina, Pezzini, Francesco, Veghini, Lisa, Delfino, Pietro, Fiorini, Claudia, Temgue Tane, Gael D., Del Curatolo, Anais, Vicentini, Caterina, Ferrari, Giorgia, Pasini, Davide, Andreani, Silvia, Lupo, Francesca, Fiorini, Elena, Lorenzon, Giulia, Lawlor, Rita T., Rusev, Borislav, Malinova, Antonia, Luchini, Claudio, Milella, Michele, Sereni, Elisabetta, Pea, Antonio, Bassi, Claudio, Bailey, Peter, Scarpa, Aldo, Bria, Emilio, and Corbo, Vincenzo

Published
2022
Full Text
View/download PDF

21. Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery

Author

Lococo, Filippo, Chiappetta, Marco, Evangelista, Jessica, Sperduti, Isabella, Nachira, Dania, Porziella, Venanzio, Congedo, Maria Teresa, Bria, Emilio, Vita, Emanuele, Cesario, Alfredo, Sassorossi, Carolina, Charles-Davies, Diepriye, Boldrini, Luca, Massaccesi, Mariangela, Valentini, Vincenzo, and Margaritora, Stefano

Published
2022
Full Text
View/download PDF

24. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study

Author

Celio, Luigi, Cortinovis, Diego, Cogoni, Alessio Aligi, Cavanna, Luigi, Martelli, Olga, Carnio, Simona, Collovà, Elena, Bertolini, Federica, Petrelli, Fausto, Cassano, Alessandra, Chiari, Rita, Zanelli, Francesca, Pisconti, Salvatore, Vittimberga, Isabella, Letizia, Antonietta, Misino, Andrea, Gernone, Angela, Bonizzoni, Erminio, Pilotto, Sara, De Placido, Sabino, and Bria, Emilio

Published
2022
Full Text
View/download PDF

26. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer.

Author

Vita, Emanuele, Monaca, Federico, Milardi, Domenico, Mastrantoni, Luca, Stefani, Alessio, Vergani, Edoardo, Russo, Jacopo, Barone, Diletta, Sparagna, Ileana, Vitale, Antonio, Scala, Alessandro, Occhipinti, Denis, Di Salvatore, Mariantonietta, Pontecorvi, Alfredo, Tortora, Giampaolo, and Bria, Emilio

Subjects
NON-small-cell lung carcinoma, ANAPLASTIC lymphoma kinase, SEXUAL dysfunction, PROTEIN-tyrosine kinase inhibitors, ANDROGENS, IMPOTENCE
Abstract

Background: It is reported that treatment with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) induces hypogonadism both in male patients with ALK‐positive cancer and in murine models. Methods: In this study, three groups, including an experimental group of male patients with ALK‐positive, advanced non–small cell lung cancer (ANSCLC) who were receiving alectinib (cohort A), a control group of female patients with ALK‐positive ANSCLC who were receiving alectinib (cohort B), and a control group of male patients with ALK‐negative ANSCLC (cohort C), prospectively underwent a full hormone assessment for androgen deficiency at 8 weeks after the start of treatment and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to an endocrinologist. Results: Ninety‐five patients were consecutively enrolled onto the study. Among sixty‐eight male patients, both median total testosterone levels (2.93 vs. 4.92 ng/ml; p =.0001) and free testosterone levels (0.11 vs. 0.17 pg/ml; p =.0002) were significantly lower in ALK‐positive ANSCLC patients in cohort A compared with ALK‐negative patients in cohort C; conversely, median FSH (10.32 vs. 17.52 mUI/ml; p =.0059) and LH levels (4.72 vs. 7.49 mUI/ml; p =.0131) were significantly higher in cohort C compared to cohort A. Median inhibin B levels were higher in ALK‐positive male patients (74.3 vs. 44.24 pg/ml; p =.0038), but all patients had inhibin B values within the normal range. The percentage of male patients who had positive scores on the Androgen Deficiency in Aging Males (ADAM) questionnaire was 62% in cohort A and 26.8% in cohort C, including eight patients who reported at least one major symptom and were referred to Andrology Unit. No significant differences in the endocrine assessment were reported between cohorts A and B. Conclusions: Symptoms of androgen deficiency should be tracked in male patients with ALK‐positive ANSCLC who are receiving alectinib, and testosterone replacement should be considered, as appropriate. Male patients with ALK‐positive advanced non–small cell lung cancer treated with first‐line alectinib had lower median total testosterone (p =.0001) and free testosterone (p =.0002) levels compared with male patients who had ALK‐negative disease and were receiving other anticancer treatments. Symptoms of hypogonadism were more frequent in ALK‐positive patients compared with ALK‐negative patients (62% vs 26.8% rates of positive score at ADAM questionnaire, respectively), suggesting the need for hormone assessment and referral to an andrologist, as appropriate. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Outcomes of Radiotherapy in Oligoprogressive Breast Cancer.

Author

Marazzi, Fabio, Masiello, Valeria, Orlandi, Armando, Moschella, Francesca, Chiesa, Silvia, Di Leone, Alba, Garufi, Giovanna, Mazzarella, Ciro, Sanchez, Alejandro M., Casa, Calogero, Bucaro, Angela, De Lauretis, Flavia, Borghesan, Niccolo, Tagliaferri, Luca, Franceschini, Gianluca, Bria, Emilio, Masetti, Riccardo, Fabi, Alessandra, Aristei, Cynthia, and Tortora, Giampaolo

Subjects
METASTATIC breast cancer, OVERALL survival, MULTIVARIATE analysis, REGRESSION analysis, PROGRESSION-free survival
Abstract

Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario. Methods: We conducted a retrospective analysis including patients with mBC who received radiation therapy (RT) for up to three sites of oligoprogression while continuing systemic therapy. The study took place between January 2014 and December 2021. Our endpoints were progression-free survival after radiotherapy (PFS-AR), the rate of discontinuation of systemic therapy (RDT) at three months post-RT, and overall survival (OS). We used Cox regression analysis to perform multivariate analysis for PFS-AR. Results: Fifty-nine patients met the inclusion criteria. The PFS-AR was 13 months (95% CI 8.5–18.8 months). At three months, the RDT was 3% (two patients). A significant difference in median PFS-AR was observed between patients in the first + second-line group and those in the subsequent line group (p = 0.03). In the multivariate analysis conducted for PFS-AR, the biologically effective dose (BED) with α/β = 4 > 100 Gy emerged as the sole significant variable (p = 0.0017). The median overall survival (OS) was 24.4 months (95% CI 17–24.4 months). Conclusions: This study is the first report on the outcomes of radiotherapy in a cohort of over 50 patients with oligoprogressive metastatic breast cancer (mBC). Our findings emphasize the significant relationship between PFS-AR, the number of ongoing lines of systemic therapy, and the BED of radiotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.

Author

Ciccarese, Chiara, Anghelone, Annunziato, Stefani, Alessio, Cigliola, Antonio, Strusi, Alessandro, D'Agostino, Filippo, Bria, Emilio, Iacovelli, Roberto, and Tortora, Giampaolo

Subjects
MAJOR adverse cardiovascular events, IMMUNE checkpoint inhibitors, PROTEIN-tyrosine kinase inhibitors, HYPERTENSION, ASYMPTOMATIC patients
Abstract

Combinations of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can be responsible for major adverse cardiovascular events (MACEs). We performed a meta-analysis to assess the relative risk (RR) of MACEs and hypertension in cancer patients treated with ICI+TKI combinations. We selected prospective trials through MEDLINE/PubMed, Cochrane Library, and ASCOMeeting abstracts. We calculated combined ORs, RRs, and 95% CIs using RevMansoftware for meta-analysis (v.5.2.3). Seven studies were selected for the analysis of MACEs (3849 patients). The incidence MACEs were 0.8% with ICI+TKI combinations, compared to 0.2% in the control arms for both any- and high-grade. ICI+TKI combinations significantly increased the risk of any- (OR = 3.21; p = 0.01) and high-grade MACEs (OR = 2.72; p = 0.05). Ten studies were selected for the analysis of hypertension (5744 patients). The incidence of treatment-related hypertension of any-grade and high-grade was41.3% (vs. 20.8%) and 26.1% (vs. 12.3%) with ICI+TKI combinations, respectively. ICI+TKI combinations significantly increased the risk of treatment-related hypertension of any-grade (RR = 2.10; p = 0.001), but not of high-grade (p = 0.11). ICI+TKI combinations increase the risk of MACEs compared to controls, although the absolute incidence is eventually low. Routine cardiovascular monitoring in asymptomatic patients is therefore not recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

Author

Ferrara, Miriam Grazia, Martini, Maurizio, D’Argento, Ettore, Forcella, Chiara, Vita, Emanuele, Di Noia, Vincenzo, Sperduti, Isabella, Bilotta, Mirna, Ribelli, Marta, Damiano, Paola, Cannella, Antonella, Stefani, Alessio, Pilotto, Sara, Carbone, Carmine, Piro, Geny, Milella, Michele, Tortora, Giampaolo, and Bria, Emilio

Published
2021
Full Text
View/download PDF

33. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Author

Di Noia, Vincenzo, D’Argento, Ettore, Pilotto, Sara, Vita, Emanuele, Ferrara, Miriam Grazia, Damiano, Paola, Ribelli, Marta, Cannella, Antonella, Virtuoso, Antonella, Fattorossi, Andrea, Ceresoli, Giovanni Luca, Milella, Michele, Beretta, Giordano Domenico, Tortora, Giampaolo, and Bria, Emilio

Published
2021
Full Text
View/download PDF

34. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Author

Cortellini, Alessio, Friedlaender, Alex, Banna, Giuseppe L., Porzio, Giampiero, Bersanelli, Melissa, Cappuzzo, Federico, Aerts, Joachim G.J.V., Giusti, Raffaele, Bria, Emilio, Cortinovis, Diego, Grossi, Francesco, Migliorino, Maria R., Galetta, Domenico, Passiglia, Francesco, Berardi, Rossana, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Tuzi, Alessandro, Gelibter, Alain, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Santoni, Matteo, Tudini, Marianna, Ghidini, Michele, Filetti, Marco, Catino, Annamaria, Pizzutilo, Pamela, Sala, Luca, Occhipinti, Mario Alberto, Citarella, Fabrizio, Russano, Marco, Torniai, Mariangela, Cantini, Luca, Follador, Alessandro, Sforza, Vincenzo, Nigro, Olga, Ferrara, Miriam G., D’Argento, Ettore, Leonetti, Alessandro, Pettoruti, Linda, Antonuzzo, Lorenzo, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Baldessari, Cinzia, Bertolini, Federica, Della Gravara, Luigi, Dal Bello, Maria Giovanna, Belderbos, Robert A., De Filippis, Marco, Cecchi, Cristina, Ricciardi, Serena, Donisi, Clelia, De Toma, Alessandro, Proto, Claudia, Addeo, Alfredo, Cantale, Ornella, Ricciuti, Biagio, Genova, Carlo, Morabito, Alessandro, Santini, Daniele, Ficorella, Corrado, and Cannita, Katia

Published
2020
Full Text
View/download PDF

36. Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review.

Author

Lococo, Filippo, Ghaly, Galal, Chiappetta, Marco, Flamini, Sara, Evangelista, Jessica, Bria, Emilio, Stefani, Alessio, Vita, Emanuele, Martino, Antonella, Boldrini, Luca, Sassorossi, Carolina, Campanella, Annalisa, Margaritora, Stefano, and Mohammed, Abdelrahman

Subjects
TREATMENT of lung tumors, CANCER relapse, INTERPROFESSIONAL relations, ARTIFICIAL intelligence, SYSTEMATIC reviews, DEEP learning, LUNG cancer, INDIVIDUALIZED medicine, MACHINE learning
Abstract

Simple Summary: Artificial intelligence (AI) has largely changed the overall management of non-small-cell lung cancer (NSCLC) by enhancing different aspects, including staging, prognosis assessment, treatment prediction, response evaluation, recurrence/prognosis prediction, and personalized prognostic assessment. In the present narrative review, we analyzed and discuss studies reporting on how AI algorithms could predict responses to various treatment modalities, such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Artificial Intelligence (AI) has revolutionized the management of non-small-cell lung cancer (NSCLC) by enhancing different aspects, including staging, prognosis assessment, treatment prediction, response evaluation, recurrence/prognosis prediction, and personalized prognostic assessment. AI algorithms may accurately classify NSCLC stages using machine learning techniques and deep imaging data analysis. This could potentially improve precision and efficiency in staging, facilitating personalized treatment decisions. Furthermore, there are data suggesting the potential application of AI-based models in predicting prognosis in terms of survival rates and disease progression by integrating clinical, imaging and molecular data. In the present narrative review, we will analyze the preliminary studies reporting on how AI algorithms could predict responses to various treatment modalities, such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. There is robust evidence suggesting that AI also plays a crucial role in predicting the likelihood of tumor recurrence after surgery and the pattern of failure, which has significant implications for tailoring adjuvant treatments. The successful implementation of AI in personalized prognostic assessment requires the integration of different data sources, including clinical, molecular, and imaging data. Machine learning (ML) and deep learning (DL) techniques enable AI models to analyze these data and generate personalized prognostic predictions, allowing for a precise and individualized approach to patient care. However, challenges relating to data quality, interpretability, and the ability of AI models to generalize need to be addressed. Collaboration among clinicians, data scientists, and regulators is critical for the responsible implementation of AI and for maximizing its benefits in providing a more personalized prognostic assessment. Continued research, validation, and collaboration are essential to fully exploit the potential of AI in NSCLC management and improve patient outcomes. Herein, we have summarized the state of the art of applications of AI in lung cancer for predicting staging, prognosis, and pattern of recurrence after treatment in order to provide to the readers a large comprehensive overview of this challenging issue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.

Author

Bria, Emilio, Morgillo, Floriana, Garassino, Marina Chiara, Ciardiello, Fortunato, Ardizzoni, Andrea, Stefani, Alessio, Verderame, Francesco, Morabito, Alessandro, Chella, Antonio, Tonini, Giuseppe, Gilli, Marina, Signore, Ester Del, Berardi, Rossana, Mencoboni, Manlio, Bearz, Alessandra, Delmonte, Angelo, Migliorino, Marta Rita, Gridelli, Cesare, Pazzola, Antonio, and Iero, Manuela

Subjects
THERAPEUTIC use of monoclonal antibodies, PATIENT safety, RESEARCH funding, TERMINATION of treatment, CARBOPLATIN, TREATMENT effectiveness, DESCRIPTIVE statistics, ETOPOSIDE, DRUG efficacy, RESEARCH, TUMOR classification, LUNG cancer, COMPARATIVE studies, PROGRESSION-free survival, OVERALL survival
Abstract

Background MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung cancer (ES-SCLC). The primary objective is the safety evaluation. Materials and Methods Patients received atezolizumab + carboplatin/etoposide Q3W for 4-6 cycles in the induction phase, followed by atezolizumab maintenance Q3W. We presented the interim analysis on safety (referring to the induction phase) and clinical effectiveness, in all patients (N  = 154) and in subgroups that received ≤3 (N  = 23), 4 (N  = 43), and 5-6 cycles (N  = 89) of induction. Results At a median follow-up of 10.5 months, 139 patients (90.3%) discontinued treatment. Serious adverse events occurred in 29.9% of patients overall, and the rate was lower in patients with 5-6 cycles (19.1%) than in those with 4 (34.9%) or ≤3 (63.6%) cycles. Immune-mediated adverse events were reported in 14.9%, 15.7%, 11.6%, and 18.2% of patients, overall and by subgroup, respectively. The median overall survival and progression-free survival were 10.7 and 5.5 months, respectively. Overall, 111 patients (71.6%) had a tumor response. Conclusions Interim results provide further evidences about safety and efficacy profile of atezolizumab + carboplatin/etoposide treatment in a ES-SCLC patient population closer to that observed in clinical practice. Clinical Trial Registration Eudract No. 2019-001146-17, NCT04028050. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, Marina Chiara, Whisenant, Jennifer G, Huang, Li-Ching, Trama, Annalisa, Torri, Valter, Agustoni, Francesco, Baena, Javier, Banna, Giuseppe, Berardi, Rossana, Bettini, Anna Cecilia, Bria, Emilio, Brighenti, Matteo, Cadranel, Jacques, De Toma, Alessandro, Chini, Claudio, Cortellini, Alessio, Felip, Enriqueta, Finocchiaro, Giovanna, Garrido, Pilar, Genova, Carlo, Giusti, Raffaele, Gregorc, Vanesa, Grossi, Francesco, Grosso, Federica, Intagliata, Salvatore, La Verde, Nicla, Liu, Stephen V, Mazieres, Julien, Mercadante, Edoardo, Michielin, Olivier, Minuti, Gabriele, Moro-Sibilot, Denis, Pasello, Giulia, Passaro, Antonio, Scotti, Vieri, Solli, Piergiorgio, Stroppa, Elisa, Tiseo, Marcello, Viscardi, Giuseppe, Voltolini, Luca, Wu, Yi-Long, Zai, Silvia, Pancaldi, Vera, Dingemans, Anne-Marie, Van Meerbeeck, Jan, Barlesi, Fabrice, Wakelee, Heather, Peters, Solange, and Horn, Leora

Published
2020
Full Text
View/download PDF

40. Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model

Author

Carbognin, Luisa, Simbolo, Michele, Caliò, Anna, Vicentini, Caterina, Delfino, Pietro, Sperduti, Isabella, Fassan, Matteo, Schettini, Francesco, Dieci, Maria Vittoria, Griguolo, Gaia, Pilotto, Sara, Fiorio, Elena, Arpino, Grazia, Guarneri, Valentina, De Placido, Sabino, Conte, Pierfranco, Manfrin, Erminia, Brunelli, Matteo, Scambia, Giovanni, Scarpa, Aldo, Tortora, Giampaolo, and Bria, Emilio

Published
2020
Full Text
View/download PDF

41. Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer

Author

Caffo, Orazio, Wissing, Michel, Bianchini, Diletta, Bergman, Andries, Thomsen, Frederik B., Schmid, Sebastian, Yu, Evan Y., Bournakis, Evangelos, Sella, Avishay, Zagonel, Vittorina, De Giorgi, Ugo, Tucci, Marcello, Gelderblom, Hans, Galli, Luca, Pappagallo, Giovanni, Bria, Emilio, Sperduti, Isabella, and Oudard, Stephane

Published
2020
Full Text
View/download PDF

43. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Author

Cortellini, Alessio, Tiseo, Marcello, Banna, Giuseppe L., Cappuzzo, Federico, Aerts, Joachim G. J. V., Barbieri, Fausto, Giusti, Raffaele, Bria, Emilio, Cortinovis, Diego, Grossi, Francesco, Migliorino, Maria R., Galetta, Domenico, Passiglia, Francesco, Santini, Daniele, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Tuzi, Alessandro, Gelibter, Alain, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Gori, Stefania, De Tursi, Michele, Mansueto, Giovanni, Zoratto, Federica, Santoni, Matteo, Tudini, Marianna, Rijavec, Erika, Filetti, Marco, Catino, Annamaria, Pizzutilo, Pamela, Sala, Luca, Citarella, Fabrizio, Marco, Russano, Torniai, Mariangela, Cantini, Luca, Targato, Giada, Sforza, Vincenzo, Nigro, Olga, Ferrara, Miriam G., D’Argento, Ettore, Buti, Sebastiano, Bordi, Paola, Antonuzzo, Lorenzo, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Baldessari, Cinzia, Della Gravara, Luigi, Dal Bello, Maria Giovanna, Belderbos, Robert A., Bironzo, Paolo, Carnio, Simona, Ricciardi, Serena, Grieco, Alessio, De Toma, Alessandro, Proto, Claudia, Friedlaender, Alex, Cantale, Ornella, Ricciuti, Biagio, Addeo, Alfredo, Metro, Giulio, Ficorella, Corrado, and Porzio, Giampiero

Published
2020
Full Text
View/download PDF

44. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Author

Pizzuti, Laura, Barba, Maddalena, Mazzotta, Marco, Krasniqi, Eriseld, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Sergi, Domenico, Marinelli, Daniele, Paoletti, Giancarlo, Tomao, Silverio, Botticelli, Andrea, Marchetti, Paolo, Tinari, Nicola, Grassadonia, Antonino, Valerio, Maria Rosaria, Mirabelli, Rosanna, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Meattini, Icro, Pistelli, Mirco, Giotta, Francesco, Lorusso, Vito, Garufi, Carlo, Russo, Antonio, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Vaccaro, Angela, Perracchio, Letizia, di Benedetto, Anna, Daralioti, Theodora, Sperduti, Isabella, De Maria, Ruggero, Di Leo, Angelo, Sanguineti, Giuseppe, Ciliberto, Gennaro, and Vici, Patrizia

Published
2021
Full Text
View/download PDF

46. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations

Author

Simbolo, Michele, Barbi, Stefano, Fassan, Matteo, Mafficini, Andrea, Ali, Greta, Vicentini, Caterina, Sperandio, Nicola, Corbo, Vincenzo, Rusev, Borislav, Mastracci, Luca, Grillo, Federica, Pilotto, Sara, Pelosi, Giuseppe, Pelliccioni, Serena, Lawlor, Rita T., Tortora, Giampaolo, Fontanini, Gabriella, Volante, Marco, Scarpa, Aldo, and Bria, Emilio

Published
2019
Full Text
View/download PDF

49. Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.

Author

Rossi, Sabrina, Pagliaro, Arianna, Finocchiaro, Giovanna, Marinello, Arianna, Giordano, Laura, Bria, Emilio, Stefani, Alessio, Vitale, Antonio, Toschi, Luca, D'Argento, Ettore, and Santoro, Armando

Abstract

Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). Results: A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS-mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with KRAS-positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. Conclusion: This study suggests a correlation between KRAS status and response to pembrolizumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.

Author

Cazzaniga, Marina Elena, Pronzato, Paolo, Amoroso, Domenico, Bernardo, Antonio, Biganzoli, Laura, Bisagni, Giancarlo, Blasi, Livio, Bria, Emilio, Cognetti, Francesco, Crinò, Lucio, De Laurentiis, Michelino, Del Mastro, Lucia, De Placido, Sabino, Beano, Alessandra, Ferraù, Francesco, Foladore, Silva, Forcignanò, Rosachiara, Gamucci, Teresa, Garrone, Ornella, and Gennari, Alessandra

Subjects
CONFIDENCE intervals, ONCOGENES, METASTASIS, ANTINEOPLASTIC agents, HYDROCARBONS, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, CELL lines, BEVACIZUMAB, ODDS ratio, PROGRESSION-free survival, BREAST tumors, LONGITUDINAL method, OVERALL survival, EVALUATION
Abstract

Simple Summary: Breast cancer is one of the most common oncological diseases among women in Western Countries and Italy as well. GIM 13-AMBRA is a patient journey study regarding how the prognosis of metastatic breast cancer patients has changed in the last decades as a result of the introduction of new drugs in clinical practice. This study also provides information regarding the different natural histories of breast cancer according to the presence or absence of hormone receptors and HER2 receptors. GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes–based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79–19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months—95% CI 5.7–9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7–15.1) and Luminal B patients (11.8 months, 95% CI 10.3–12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3–6.5 vs. Luminal A—9.4, 95% CI 8.1–10.7, and Luminal B—7.7 95% CI 6.8–8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8–37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2–31.2) and TNBC (18.5 months, 95% CI 16–20.1, F-ratio 7.44, p = 0.0006). The GIM 13—AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results